Deciphering ventricular GLP-1 action: Time for a change of heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 10, 2014, Pages H1390-H1392

  Ussher, John R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

CLINICAL TRIAL (TOPIC); EDITORIAL; HEART MUSCLE CELL; HEART PROTECTION; HORMONAL THERAPY; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; MALE; METABOLISM;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HYPOGLYCEMIC AGENTS; MALE; MYOCYTES, CARDIAC; NADPH OXIDASE;

EID: 84922393285     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00680.2014     Document Type: Editorial

References (21)

1. Balteau M, Van Steenbergen A, Timmermans AD, Dessy C, Behets- Wydemans G, Tajeddine N, Castanares-Zapatero D, Gilon P, Vanoverschelde JL, Horman S, Hue L, Bertrand L, Beauloye C. AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes. Am J Physiol Heart Circ Physiol 307: H1120-H1133, 2014.
2. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, Drucker DJ, Husain M. Glucagon-like peptide (GLP)-1(9 -36)amidemediated cytoprotection is blocked by exendin(9 -39) yet does not require the known GLP-1 receptor. Endocrinology 151: 1520-1531, 2010.
3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and -independent pathways. Circulation 117: 2340-2350, 2008.
4. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17: 819-837, 2013.
5. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, Liu Z. Glucagonlike peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes 61: 888-896, 2012.
6. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
7. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, Zimmermann B, Voigt K. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58: 149-156, 1995.
8. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19: 567-575, 2013.
9. Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Kober L, Treiman M, Holst JJ, Engstrom T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 33: 1491- 1499, 2012.
10. Lonborg J, Vejlstrup N, Kelbaek H, Nepper-Christensen L, Jorgensen E, Helqvist S, Holmvang L, Saunamaki K, Botker HE, Kim WY, Clemmensen P, Treiman M, Engstrom T. Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study. Diabetes 63: 2474-2485, 2014.
11. Mulvihill EE, Drucker DJ. Pharmacology, physiology and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev er20141035, 2014.
12. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-H2408, 2005.
13. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965, 2004.
14. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983, 2009.
15. Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 1: 153-160, 2008.
16. Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, Gribble FM, Reimann F. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63: 1224-1233, 2014.
17. Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP- 1(28 -36)amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 167: 177-184, 2011.
18. Ussher JR, Baggio LL, Campbell JE, Mulvihill EE, Kim M, Kabir MG, Cao X, Baranek BM, Stoffers DA, Seeley RJ, Drucker DJ. Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP- 1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection. Mol Metab 3: 507-517, 2014.
19. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res 114: 1788-1803, 2014.
20. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 33: 187-215, 2012.
21. Ussher JR, Sutendra G, Jaswal JS. The impact of current and novel anti-diabetic therapies on cardiovascular risk. Future Cardiol 8: 895-912, 2012.